… DMD patients eligible for either exon-51, exon-53 or exon-45 skipping treatments account …
DMD patients are not eligible for either exon-51, exon-53, or exon-45 skipping therapies and …

… marked improvements in clinical outcomes when treated with … exon 20 point mutations were
PACC mutations; that exon 20 … stratified by either structure–function-based groups or exon-…

… induces hydrolyzing reaction by cleaving phosphodiester bond at either at 3′ or 5′ ends.
It … modalities to achieve maximal clinical outcome and to bypass the mentioned challenges. …

… exon deletion event as either a large indel (BRCA1 c.5053_5136del), a copy number loss (…
exon 18 loss), or a small structural rearrangement (BRCA1 [exon 1-17] - BRCA1 [exon 19-22])…

… We designed two such U7snRNAs, targeting either the exon 2 splice acceptor (sequence
A) or splice donor (sequence C) sites, and cloned four copies (two of each sequence) into an …

… exons of either EWSR1 or FUS to the 3′ coding exons of … most commonly linked exons
1–8 of EWSR1 to exons 5–7 of … the clinical outcomes for these tumors, we next curated clinical …

… primers (FPs) that bind to either exon 7-8 junction or exon 6-8 junction and a … on clinical
outcome, we plotted outcomes of the activity of the identified variants and the clinical outcomes in …

… of either the distal region of PML exon 6 (from 8 to 146 nucleotides), or the entire exon 6, as
… are associated with elevated WBC counts and poorer clinical outcomes [130], in the largest …

… Reflects either re-treatment of a patient with platinum after an intervening LOT or a … , may
lead to modifications in treatment sequencing protocols and improvements in clinical outcomes. …

… has significantly improved clinical outcomes in patients with … A clinically relevant mutation
was identified by either tissue-… Tissue-NGS on this case identified the EGFR exon 19 mutation …